Discontinued — last reported Q4 '24
Other neuroscience — Revenue
Eli Lilly Other neuroscience — Revenue decreased by 50.0% to $58.60M in Q4 2024 compared to the prior quarter. Over 3 years (FY 2021 to FY 2024), Other neuroscience — Revenue shows an upward trend with a 16.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful lifecycle management or stable demand for mature products, while a decrease often reflects product obsolescence, patent expirations, or a strategic shift toward newer, higher-growth therapeutic areas.
Detailed definition
This metric represents the total net sales generated by the company's legacy or non-core neuroscience product portfolio....
Peer comparison
Comparable to 'Other' or 'Legacy' product segment revenues reported by diversified pharmaceutical peers, often used to measure the tail-end revenue contribution of aging drug portfolios.
lly_segment_other_neuroscience_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $84.90M | $76.50M | $74.60M | $74.20M | $69.60M | $60.60M | $70.70M | $206.20M | $217.90M | $118.20M | $0.00 | $163.40M | $147.50M | $117.20M | $58.60M |
| QoQ Change | — | -9.9% | -2.5% | -0.5% | -6.2% | -12.9% | +16.7% | +191.7% | +5.7% | -45.8% | -100.0% | — | -9.7% | -20.5% | -50.0% |
| YoY Change | — | — | — | — | -18.0% | -20.8% | -5.2% | +177.9% | +213.1% | +95.0% | -100.0% | -20.8% | -32.3% | -0.8% | — |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's other neuroscience — revenue?
- Eli Lilly (LLY) reported other neuroscience — revenue of $58.60M in Q4 2024.
- What is the long-term trend for Eli Lilly's other neuroscience — revenue?
- Over 3 years (2021 to 2024), Eli Lilly's other neuroscience — revenue has grown at a 16.3% compound annual growth rate (CAGR), from $309.50M to $486.70M.
- What does other neuroscience — revenue mean?
- Total revenue generated from the company's secondary or legacy neuroscience product line.